INew York City, eseyiphinde yaba umqedazwe walolu bhubhane e-US, isiqophe cishe amacala amasha angama-50,000 ngoDisemba 24 kuphela. Leli inani eliphakeme kakhulu losuku olulodwa esifundazweni kusukela kwaqala lolu bhubhane.

Ngokufanayo nango-2020, ukukhuphuka kwezwe lonke ezimeni kube yingozi emnothweni ngenxa yemikhawulo, ethinte imicimbi yezemidlalo, ukuthunyelwa kwemikhumbi futhi ikakhulukazi ukuhamba, nezinkulungwane zezindiza ezikhanseliwe kuyo yonke impelasonto yamaholide. Emhlabeni jikelele, izindiza zikhansele izindiza ezingaphezu kuka-6,000 ngosuku olwandulela uKhisimusi, uKhisimusi nangosuku olulandela uKhisimusi, ngokusho kweFlightAware. Todos Medical Ltd., Pfizer Inc., Moderna, Inc., Inovio Pharmaceuticals, Inc., Merck & Co., Inc.

Ngokuka-Anthony S. Fauci, umeluleki omkhulu wezokwelapha kuMongameli u-Biden, kuzobaluleka kakhulu, “ukuthi sithole amandla amakhulu okuhlola, ikakhulukazi lapho isidingo sokuhlolwa siphezulu kakhulu, nenhlanganisela yokwahluka kwe-Omicron uqobo. , kanye nenkathi yamaholide, lapho abantu befuna ukuthola lelo zinga elengeziwe lokuqinisekisa ukuthi bavikelekile, ngisho noma ugonyiwe futhi uthuthukisiwe.”

I-Todos Medical Ltd. imemezele izolo ukuthi, "i-CLIA/CAP PCR ezenzakalela kakhulu futhi ilabhorethri ye-cPass evimbela amasosha omzimba e-COVID-19 i-Provista Diagnostics izuze amarekhodi alandelanayo amasonto onke okuhlolwa kwe-COVID PCR emasontweni kaDisemba 13, 2021 nangoDisemba 20, 2021. Amavolomu okuhlola i-COVID PCR ayeqhutshwa ngokuyinhloko ibhizinisi zelebhu yereferensi evela kulebhu yokuhlola ye-PCR yaseNew York engakwazi ukufeza isidingo sokuhlola endaweni yayo. INkampani iphinde yangena esivumelwaneni esisha sezinsizakalo zaselabhorethri nodokotela osekelwe eNew Jersey wokuhlolwa kwe-COVID PCR kanye nokuhlolwa kwe-COVID cPass okwehlisa amandla omzimba.

'Isidingo sokuhlolwa kwe-PCR sikhula ngokushesha emaphaketheni e-United States, futhi silindele ukuthi lokhu kuqhubeke ngale kwamaholide njengoba abantu, izikole nabaqashi befuna ukudala izindawo eziphephile, ikakhulukazi ezindaweni ezinamazinga aphansi okugoma,' kusho uGerald E. Commissiong, uMongameli kanye ne-CEO ye-Todos Medical, inkampani engumzali ye-Provista Diagnostics. 'Uma kubhekwa igunya elilindile 'lokugoma noma ukuhlolwa' elivela ku-Biden Administration elizobeka izidingo zokuhlola ku-38% wabantu abadala baseMelika abangakagonyelwa ngokugcwele i-COVID-19, sibona ukushoda kwakamuva kokuhlolwa kuhlanganiswe ne kusalindwe igunya lokudala isidingo sokunyuka okubaluleke kakhulu ekuhlolweni kwe-COVID PCR yesikhathi eside ye-Provista. Uma ungeza ikhono le-Omicron lokubalekela umgomo noma ukuzivikela okutholwe ukutheleleka, kanye nezinselele zokufinyelela nokuthembeka kokuhlolwa okusheshayo kwe-antigen okudume kakhulu ngokuveza imiphumela engemihle engamanga, ukuhlolwa kwe-COVID PCR okunezikhathi zokushintsha ngokushesha kuvela njengomthombo othembeke kakhulu futhi onokwethenjelwa. yolwazi lokwazi isimo somuntu sokutheleleka nge-COVID.'

UMnu. Commissiong uqhube wathi, 'Ngaphezu kwalokho, uma uhlanganisa lezi zimo kanye nokukhuphuka kwakamuva kwentshisekelo kuma-booster to buttress vaccine noma amasosha omzimba atholwe ukutheleleka ngokumelene ne-Omicron, siqala ukubona ukwanda okuphawulekayo kwentshisekelo yokuhlolwa kwe-cPass neutralizing antibody ukuze kuqashwe. amazinga ajikelezayo okuhlolwa kwe-antibody anciphisa futhi avumele iziguli ukuba zenze izinqumo ezisheshayo, eziqhutshwa idatha ukuze zithole izithombe ezikhuthazayo, ikakhulukazi uma kunikezwe idatha evelayo ephakamisa ukuthi ama-antibody-titers aphezulu akhiqizwa kusukela ekudubuleni kwakamuva yiwona okungenzeka kakhulu ukuvikela umuntu ku-Omicron. ukutheleleka.'

Idatha yakamuva evela kwa-Israel iphakamisa ukuncishiswa kwama-antibody titers ekuphenduleni umgomo we-Pfizer/BioNTech Comirnaty uqala ukuncipha ngemva kwezinyanga ezi-4 kusukela ekugonyweni okugcwele, nokuthi amashothi akhuthazayo e-Comirnaty aqala ukuncipha ngemva kwamaviki angu-10 kusukela ekudutshulweni kwe-booster. Ishothi yesine (“i-Second Booster”) isanda kugunyazwa kwa-Israel kubantu abasengozini yokuzivikela komzimba kanye nalabo abaneminyaka engu-60+, futhi kuyaqhubeka ucwaningo lokunquma ukuqina kwe-Second Booster kubantu abaningi.

I-Pfizer Inc. imemezele ngesonto eledlule ukuthi i-US Food and Drug Administration (FDA) igunyaze ukusetshenziswa okuphuthumayo kwamaphilisi e-PAXLOVID™ (nirmatrelvir [PF-07321332] namaphilisi e-ritonavir) ekwelapheni i-COVID-19 emaphakathi ukuya kokumaphakathi kubantu abadala. kanye neziguli zezingane (ezineminyaka eyi-12 nangaphezulu ezinesisindo esingenani ngama-40 kg [88 lbs]) ezinemiphumela emihle yokuhlolwa kwegciwane okuqondile kwa-SARS-CoV-2, futhi ezisengozini enkulu yokudlulela ku-COVID-19 enzima, okuhlanganisa ukulaliswa esibhedlela noma ukufa. Ukwelashwa kuhlanganisa i-nirmatrelvir, inhibitor yenoveli eyinhloko ye-protease (Mpro) evela ezindaweni zokucwaninga ze-Pfizer, eyaklanywa ngokuqondile ukuvimba umsebenzi we-SARS-CoV-2 Mpro, i-enzyme okudingeka i-coronavirus iphindaphinde. “Ukugunyazwa kwanamuhla kwe-PAXLOVID kumelela esinye isibonelo esihle kakhulu sokuthi isayensi izosisiza kanjani ukuthi sinqobe lo bhubhane, okuthi, ngisho neminyaka emibili, luqhubeke nokuphazamisa futhi lucekele phansi izimpilo zabantu emhlabeni wonke. Lokhu kwelashwa okuphumelelayo, okukhonjiswe ukuthi kunciphisa kakhulu ukulaliswa kanye nokufa kwabantu futhi kungathathwa ekhaya, kuzoshintsha indlela esiphatha ngayo i-COVID-19, futhi ngethemba ukuthi kuzosiza ekwehliseni ezinye zezingcindezi ezibalulekile ezibhekene nezinhlelo zethu zezempilo nezibhedlela, ”kusho u-Albert. Bourla, uSihlalo kanye noMphathi Omkhulu, uPfizer. "I-Pfizer isimi ngomumo ukuqalisa ukulethwa e-US ngokushesha ukuze isize ukuthi i-PAXLOVID ibe sezandleni zeziguli ezifanele ngokushesha okukhulu."

I-Moderna, Inc. yamemezela ngo-December 20, idatha yokuqala ye-antibody eyenza ingasebenzi ngokumelene nokuhluka kwe-Omicron kulandela amakhandidethi akhuthazayo eNkampani kumazinga womthamo ongu-50 µg no-100 µg. I-booster egunyazwe njengamanje engu-50 µg ye-mRNA-1273 inyuse amazinga e-antibody e-omicron cishe izikhathi ezingama-37 uma kuqhathaniswa namazinga okuthuthukisa ngaphambili kanye nomthamo ongu-100 µg we-mRNA-1273 yenyuse amazinga e-antibody angasebenzi cishe ngokuphindwe ka-83 uma kuqhathaniswa namazinga okuthuthukisa ngaphambili. “Ukwanda okumangazayo kwamacala e-COVID-19 avela ezinhlobonhlobo ze-Omicron kuthinta bonke abantu. Kodwa-ke, le mininingwane ekhombisa ukuthi i-Moderna COVID-19 booster egunyaziwe njengamanje ingakhuphula amazinga e-antibody ngokuphindwe ngama-37 aphezulu kunamazinga angaphambi kokukhulisa iyasiqinisekisa, ”kusho uStéphane Bancel, oyiChief Executive Officer yeModerna. "Ukuze siphendule kulokhu kuhluka okusuleleka kakhulu, iModerna izoqhubeka nokuqhubekisela phambili umuntu ozongenela ukhetho olukhethekile lwe-Omicron ekuhlolweni komtholampilo uma kwenzeka kudingekile ngokuzayo. Sizoqhubeka futhi nokukhiqiza nokwabelana ngedatha kuwo wonke amasu ethu okuthuthukisa neziphathimandla zezempilo zomphakathi ukuze zizisize zenze izinqumo ezisekelwe ebufakazini ngamasu angcono kakhulu okugomela i-SARS-CoV-2.”

I-Inovio Pharmaceuticals, Inc. imemezele izibuyekezo ngenyanga edlule ngohlelo lweSigaba 3 lwe-VGX-3100 yezilonda ezihambisana nomlomo wesibeletho ezihlotshaniswa ne-HPV ze-squamous intraepithelial lesions (HSIL), okuhlanganisa nokulandelela konyaka owodwa kokusebenza kahle nedatha yokuphepha kubahlanganyeli abavela ku-REVEAL1. , eqedela ukubhalisa ku-REVEAL2, kanye nokuthuthukisa ikhandidethi layo le-biomarker yangaphambi kokwelashwa le-VGX-3100 ukuze ithuthukiswe nge-QIAGEN. Ngaphezu kwalokho, uzakwethu wokuthuthukisa i-INOVIO ngaphakathi kwe-Greater China (izwekazi lase-China, i-Hong Kong, i-Macao, i-Taiwan), i-ApolloBio Corp. (“i-ApolloBio”), idose umhlanganyeli wokuqala ocwaningweni oluhlukile lweSigaba sesi-3 e-China. UDkt. J. Joseph Kim, uMongameli kanye ne-CEO ye-INOVIO, uthe, “Senza inqubekelaphambili eqinile ekuthuthukiseni i-INOVIO's immunotherapies elapha i-HSIL yomlomo wesibeletho ehlobene ne-HPV. Uma ingelashwa, i-HSIL yomlomo wesibeletho ingase ithuthukele kumdlavuza. I-VGX-3100 inamandla okuba eyokuqala evunyiwe yokwelashwa kwamasosha omzimba kanye nenye indlela engahlinzeki kwabesifazane abane-HSIL yomlomo wesibeletho futhi sibheke ngabomvu ukuthuthukisa imizamo yethu kusukela ezifundweni zethu zeSigaba 3 ngokwenza ukuhweba.”

I-Merck & Co., Inc. imemezele ekuqaleni kwale nyanga ukuthi i-New England Journal of Medicine ishicilele okutholwe ocwaningweni lweSigaba 3 lwe-MOVe-OUT oluhlola i-molnupiravir, umuthi ophenywayo we-antiviral odluliselwa ngomlomo, kubantu abadala abangalaliswa esibhedlela abasengcupheni ephezulu abane-COVID emnene ukuya emaphakathi. -19. Idatha evela ku-MOVe-OUT ibonise ukuthi ukwelashwa kusenesikhathi nge-molnupiravir kwehlisa kakhulu ingcuphe yokulaliswa esibhedlela noma yokushona engozini enkulu, abantu abadala abangagonyiwe abane-COVID-19. I-Merck yenza i-molnupiravir ngokubambisana ne-Ridgeback Biotherapeutics. I-Molnupiravir igunyazwe e-United Kingdom njenge-antiviral yokuqala yomlomo yokwelapha i-COVID-19 emaphakathi ukuya kwesesilinganisweni kubantu abadala ngokuhlolwa okuqondile kwe-SARS-CoV-2 futhi abanesici okungenani esisodwa engcupheni yokuthola ukugula okunzima. I-European Medicines Agency (EMA) ikhiphe umbono wesayensi omuhle nge-molnupiravir ngaphansi kwe-Article 5.3 Regulation 726/2004, okuhloswe ngayo ukweseka ukuthathwa kwezinqumo kuzwelonke mayelana nokusetshenziswa okungenzeka kwe-molnupiravir ngaphambi kokugunyazwa ukumaketha. Izicelo zokulawula ziyabuyekezwa noma zisendleleni yokuthunyelwa, okuhlanganisa nezicelo zokugunyazwa ukusetshenziswa kwezimo eziphuthumayo (i-EUA) yi-US Food and Drug Administration (FDA) kanye Nomnyango Wezempilo, Wezabasebenzi Nenhlalakahle Yase-Japan.

LOKHO ONGAKUTHATHE KULESI SIHLOKO:

Commissiong continued, ‘Further, when you combine these realities with a recent uptick in interest in boosters to buttress vaccine or infection-acquired immunity against Omicron, we are beginning to see a marked increase in interest for the cPass neutralizing antibody test to monitor levels of circulating neutralizing antibody testing and allow patients to make rapid, data-driven decisions to get their booster shots, especially given emerging data that suggests high neutralizing antibody-titers produced from a recent booster shot is the most likely to protect an individual against Omicron infection.
Fauci, chief medical adviser to President Biden, it is going to be very important, “that we get a greater capability of testing, particularly when the demand for testing is so high, with the combination of the Omicron variant itself, as well as the holiday season, where people want to get that extra level of assuredness that they’re protected, even if you are vaccinated and boosted.
Food and Drug Administration (FDA) has authorized the emergency use of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.